Axitinib Poised To Join Pfizer's RCC Drug Portfolio In 2012
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer Inc.'s second-generation VEGF inhibitor axitinib has been granted a standard 10-month review by FDA for the second-line treatment of advanced renal cell carcinoma, positioning it for a potential launch in the first half of 2012.